Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Vile

Showing results (21-30 of 91) with videos related to

Pageof 10
Sort By:
Current Cancer Drug Targets|March 6, 2010
The biology of the sodium iodide symporter and its potential for targeted gene deliveryMohan Hingorani, Christine Spitzweg, Georges Vassaux, et al.
Molecular Therapy. Oncology|October 15, 2024
APOBEC3B expression in 293T viral producer cells drives mutations in chimeric antigen receptors and reduces CAR T cell efficacyJack Swanson, Jason Tonne, Thanich Sangsuwannukul, et al.
Molecular Therapy. Nucleic Acids|May 23, 2013
CARbodies: Human Antibodies Against Cell Surface Tumor Antigens Selected From Repertoires Displayed on T Cell Chimeric Antigen ReceptorsVanesa Alonso-Camino, David Sánchez-Martín, Marta Compte, et al.
Human Gene Therapy|August 7, 2002
Cells as vehicles for cancer gene therapy: the missing link between targeted vectors and systemic delivery?Kevin Harrington, Luis Alvarez-Vallina, Marka Crittenden, et al.
Frontiers in Oncology|July 27, 2016
Sickle Cells Abolish Melanoma Tumorigenesis in Hemoglobin SS Knockin Mice and Augment the Tumoricidal Effect of Oncolytic Virus In VivoChiang Wang Sun, Candice Willmon, Li-Chen Wu, et al.
Molecular Therapy Oncolytics|March 5, 2021
Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate TumorsNicola E Annels, Guy R Simpson, Mick Denyer, et al.
Molecular Cancer|February 23, 2011
Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune primingLynette Steele, Fiona Errington, Robin Prestwich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2006
Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapyFiona Errington, Andrew Bateman, Tim Kottke, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 16, 2010
The effect of cell cycle synchronization on tumor sensitivity to reovirus oncolysisLucy Heinemann, Guy R Simpson, Nicola E Annels, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 28, 2010
Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamideCandice Willmon, Rosa M Diaz, Phonphimon Wongthida, et al.
Pageof 10

Showing results (21-30 of 91) with videos related to

Sort By:
Pageof 10
Current Cancer Drug Targets|March 6, 2010
The biology of the sodium iodide symporter and its potential for targeted gene deliveryMohan Hingorani, Christine Spitzweg, Georges Vassaux, et al.
Molecular Therapy. Oncology|October 15, 2024
APOBEC3B expression in 293T viral producer cells drives mutations in chimeric antigen receptors and reduces CAR T cell efficacyJack Swanson, Jason Tonne, Thanich Sangsuwannukul, et al.
Molecular Therapy. Nucleic Acids|May 23, 2013
CARbodies: Human Antibodies Against Cell Surface Tumor Antigens Selected From Repertoires Displayed on T Cell Chimeric Antigen ReceptorsVanesa Alonso-Camino, David Sánchez-Martín, Marta Compte, et al.
Human Gene Therapy|August 7, 2002
Cells as vehicles for cancer gene therapy: the missing link between targeted vectors and systemic delivery?Kevin Harrington, Luis Alvarez-Vallina, Marka Crittenden, et al.
Frontiers in Oncology|July 27, 2016
Sickle Cells Abolish Melanoma Tumorigenesis in Hemoglobin SS Knockin Mice and Augment the Tumoricidal Effect of Oncolytic Virus In VivoChiang Wang Sun, Candice Willmon, Li-Chen Wu, et al.
Molecular Therapy Oncolytics|March 5, 2021
Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate TumorsNicola E Annels, Guy R Simpson, Mick Denyer, et al.
Molecular Cancer|February 23, 2011
Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune primingLynette Steele, Fiona Errington, Robin Prestwich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2006
Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapyFiona Errington, Andrew Bateman, Tim Kottke, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 16, 2010
The effect of cell cycle synchronization on tumor sensitivity to reovirus oncolysisLucy Heinemann, Guy R Simpson, Nicola E Annels, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 28, 2010
Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamideCandice Willmon, Rosa M Diaz, Phonphimon Wongthida, et al.
Pageof 10